	US 12,329,771 B2
	Methods relating to lung cancer
Ana Brandusa Pavel, New York, NY (US); Joshua David Campbell, Sharon, MA (US); Marc Elliott Lenburg, Brookline, MA (US); and Avrum Elliot Spira, Newton, MA (US)
Assigned to Trustees of Boston University, Boston, MA (US)
Filed by Trustees of Boston University, Boston, MA (US)
Filed on Jul. 19, 2022, as Appl. No. 17/867,929.
Application 17/867,929 is a division of application No. 16/828,053, filed on Mar. 24, 2020, granted, now 11,426,423.
Application 16/828,053 is a division of application No. 16/391,473, filed on Apr. 23, 2019, granted, now 10,632,140, issued on Apr. 28, 2020.
Application 16/391,473 is a continuation of application No. 15/877,447, filed on Jan. 23, 2018, granted, now 10,314,855, issued on Jun. 11, 2019.
Claims priority of provisional application 62/449,223, filed on Jan. 23, 2017.
Prior Publication US 2023/0255998 A1, Aug. 17, 2023
Int. Cl. A61K 31/7105 (2006.01); A61P 35/00 (2006.01); C12Q 1/6825 (2018.01); C12Q 1/6886 (2018.01); G01N 33/574 (2006.01)

CPC A61K 31/7105 (2013.01) [A61P 35/00 (2018.01); C12Q 1/6825 (2013.01); C12Q 1/6886 (2013.01); G01N 33/57423 (2013.01); C12Q 2539/10 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/178 (2013.01)]

5 Claims

1. A method of treating lung cancer in a subject in need thereof, the method comprising administering to the subject:

a) an agonist of at least 1 miRNA selected from the group consisting of: miR-324-5p; miR-769-3p; miR-618; miR-338-5p; miR-210; miR-450a-5p; miR-30b-5p; miR-450a-5p; miR-652-3p; miR-107; miR-887; miR-147b; miR-31-5p; miR-29c-5p; miR-324-3p; miR-345-5p; miR-450b-5p; miR-769-5p; miR-326; miR-940; miR-582-5p; miR-31-3p; miR-378i; miR-505-3p; miR-1249; miR-1260b; miR-3200-3p; miR-425-3p; miR-4791; miR-1296; and miR-4677-3p; or

b) an inhibitor of at least 1 miRNA selected from the group consisting of: miR-375; miR-24-1-5p; miR-130b-5p; miR-183-5p; and miR-203a.